Business Description
Lunai Bioworks Inc
NAICS : 325414
SIC : 2834
ISIN : US29350E1047
Total Employee Number:
29Description
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.24 | |||||
Equity-to-Asset | -0.97 | |||||
Debt-to-Equity | -0.15 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -116.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 20.7 | |||||
3-Year EPS without NRI Growth Rate | 47.2 | |||||
3-Year FCF Growth Rate | 45.8 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
14-Day RSI | 22.06 | |||||
12-1 Month Momentum % | -60.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.19 | |||||
Quick Ratio | 0.19 | |||||
Cash Ratio | 0.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.5 | |||||
Shareholder Yield % | -41.94 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -46885.71 | |||||
Net Margin % | -610871.43 | |||||
EBITDA Margin % | -602542.86 | |||||
FCF Margin % | -25122.22 | |||||
OCF Margin % | -25122.22 | |||||
ROE % | -2076.18 | |||||
ROA % | -429.2 | |||||
ROIC % | -29.65 | |||||
3-Year ROIIC % | -7 | |||||
ROC (Joel Greenblatt) % | -25553.67 | |||||
ROCE % | -1951.97 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 320 | |||||
EV-to-EBIT | -0.07 | |||||
EV-to-EBITDA | -0.07 | |||||
EV-to-Revenue | 400.57 | |||||
EV-to-FCF | -1.6 | |||||
Earnings Yield (Greenblatt) % | -1428.57 | |||||
FCF Yield % | -51.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lunai Bioworks Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.018 | ||
| EPS (TTM) (€) | -53.205 | ||
| Beta | -3.2723 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.92 | ||
| Volatility % | 98.26 | ||
| 14-Day RSI | 22.06 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 8.368 | ||
| 12-1 Month Momentum % | -60.23 | ||
| 52-Week Range (€) | 8.016 - 20.76 | ||
| Shares Outstanding (Mil) | 4.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lunai Bioworks Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lunai Bioworks Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2026-11-13 | In 107 days | ||
| General meeting for 2026 | 2026-10-30 10:00 | In 94 days | ||
| Annual report for 2026 | 2026-09-29 | In 62 days | ||
| 0.125:1 Stock Split | 2026-05-22 | 8.37 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-05-15 | 8.37 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-17 | 8.37 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-11-14 | 8.37 (+0.00%) | ||
| General meeting for 2025 | 2025-10-31 10:00 | 8.37 (+0.00%) | ||
| 0.1:1 Stock Split | 2025-09-30 | 8.37 (+0.00%) | ||
| Annual report for 2025 | 2025-09-29 | 8.70 (-3.72%) |
Show
Entries
Lunai Bioworks Inc Frequently Asked Questions
What is Lunai Bioworks Inc(STU:2Q5)'s stock price today?
The current price of STU:2Q5 is €8.37. The 52 week high of STU:2Q5 is €20.76 and 52 week low is €8.02.
When is next earnings date of Lunai Bioworks Inc(STU:2Q5)?
The next earnings date of Lunai Bioworks Inc(STU:2Q5) is 2026-11-13 Est..
Does Lunai Bioworks Inc(STU:2Q5) pay dividends? If so, how much?
Lunai Bioworks Inc(STU:2Q5) does not pay dividend.
Press Release
Articles on Lunai Bioworks Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers